Morningstar

GSK PLC ADR GSK

Morningstar Rating
Unlock
Stock XNYS Rating as of
$51.25 +0.61 (1.20%)
View Full Chart
As of Delayed Price Post-Trading: $51.33 +0.08

Company Report

View Archive

Price vs Fair Value

View History
GSK is trading at a 783% premium.
Price
$50.64
Fair Value
$49.00
Uncertainty
Medium
1-Star Price
$13.40
5-Star Price
$19.80
Economic Moat
Fcftw
Capital Allocation
Wpdcxgypj

Bulls Say, Bears Say

Bulls

GSK's portfolio has recently been augmented by launches in respiratory immunology (Exdensur), long-acting HIV drugs (Cabenuva), and oncology (Blenrep, and so on).

Bears

HIV patent pressure on GSK's key drugs will likely begin around 2028 or so, putting strong pressure on the company to succeed with its pipeline of longer acting drugs for treatment and prophylaxis.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$50.64
Day Range
$50.35–51.34
52-Week Range
$35.45–61.70
Bid/Ask
$51.11 / $51.35
Shares Outstanding
2.00B
Market Cap
$102.73B
Volume/Avg
6M / 4M

Key Statistics

Price/Earnings (Normalized)
10.89
Price/Sales
2.36
Dividend Yield (Trailing)
3.56%
Dividend Yield (Forward)
3.56%
Total Yield
5.45%

Company Profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
66,841
Website
https://www.gsk.com

Competitors

Valuation

View More
Metric
GSK
AZN
PFE
Price/Earnings (Normalized)
 10.8920.048.37
Price/Book Value
 4.335.961.62
Price/Sales
 2.364.782.31
Price/Cash Flow
 8.8318.148.55
Price/Earnings
GSK
AZN
PFE

Financial Strength

Metric
GSK
AZN
PFE
Quick Ratio
 0.510.700.85
Current Ratio
 0.790.911.25
Interest Coverage
 11.718.173.73
Quick Ratio
GSK
AZN
PFE

Profitability

Metric
GSK
AZN
PFE
Return on Assets (Normalized)
 11.47%9.16%8.40%
Return on Equity (Normalized)
 44.00%22.59%19.47%
Return on Invested Capital (Normalized)
 22.62%14.71%12.80%
Return on Assets
GSK
AZN
PFE

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
KwbqnydmkKglq$1T
 Johnson & Johnson
JNJ
LshngtslWxrp$559B
 AbbVie Inc
ABBV
WbnwpxbHfjvd$394B
 Roche Holding AG ADR
RHHBY
YckgtxddPsrn$323B
 Merck & Co Inc
MRK
ZpyjhrfgSxlkr$295B
 AstraZeneca PLC
AZN
ZrblndfklFtcc$286B
 Novartis AG ADR
NVS
KtbktnrrdFdvm$281B
 Amgen Inc
AMGN
YnnsghdlbXcnl$187B
 Novo Nordisk AS ADR
NVO
KpqsdqrdyjSrtq$186B
 Gilead Sciences Inc
GILD
RpnsxdnfMtnxm$159B

Sponsor Center